Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.
PYC Therapeutics Limited has applied for quotation on the ASX of 354,782,201 new fully paid ordinary shares, with an issue date of 12 February 2026. The securities are being admitted to quotation following a previously announced transaction, expanding the company’s listed share base and potentially enhancing its market liquidity and access to capital for future development activities.
The move signals a further step in PYC’s capital markets strategy as it progresses its therapeutics pipeline and seeks broader investor participation. The enlarged register may have implications for existing shareholders through dilution but could also support the company’s long-term funding needs and visibility within the biotechnology sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code PYC. The company operates in the therapeutics industry, focusing on the development of novel medical treatments and related biopharmaceutical technologies for healthcare markets.
Average Trading Volume: 695,691
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.4B
Learn more about PYC stock on TipRanks’ Stock Analysis page.